Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings
Jefferies analysts highlighted Oncorus (ONC), Revolution Medicines (RVMD), and Alnylam Pharmaceuticals (ALNY) as top mid-cap biotech stocks ahead of earnings. ONC received a $410 price target, RVMD is expected to exceed revenue estimates, and ALNY's target was lowered to $250. The firm cited specific catalysts and data for each company.
How this was made
The 30-second read
Why it matters
Analyst target changes provide fresh directional cues for the highlighted stocks.
Market read
The new analyst recommendations may influence short‑term trading in ONC, RVMD, and ALNY.
What to watch
Potential regulatory delays for Brukinsa and RVMD pipeline could temper expectations.
Background
Jefferies released a mid‑cap biotech watchlist ahead of Q3 earnings, adjusting price targets for three companies.
Ticker impact
Jefferies raised the price target to $410 and reaffirmed a Buy rating, citing strong Brukinsa revenue outlook.
likely upward pressure as investors price in the higher target and strong revenue expectations
Buy rating and target increase are fresh analyst actions that can move the stock immediately.
Jefferies kept a Buy rating and modeled Q3 revenue above consensus, highlighting early prescription uptake.
moderate upside as the market digests better‑than‑consensus revenue guidance
Analyst expectations are new but less aggressive than a rating upgrade, so impact is limited.
Jefferies lowered the price target to $250 from $260 while maintaining a Hold rating, citing concerns over 340B exposure.
potential downward pressure as investors adjust to the lower target
A price‑target reduction is a fresh negative signal, likely to temper the stock’s near‑term performance.
Market effects
Highlights strength in mid‑cap biotech earnings outlook, may lift peer sentiment.
U.S. biotech sector could see modest gains as analysts raise targets.
Limited to investors focused on U.S. biotech equities.
Counterpoint
Some investors may view the target raises as already priced in, limiting upside.
Key entities
- Analyst FirmJefferies
Provider of the coverage and price‑target adjustments.
